(NewsDirect)
BioVaxys CEO James Passin joins NatalieStoberman from the Proactive newsroom to discuss the company'sacquisition of TAETSoftware, a Vancouver-based clinical studiesmanagement company engaged in the development and commercialization ofthe Trial Adverse Events Tracker (TAET) technology platform.
Passin says the acquisition of TAETCO provides BioVaxys with athird low-risk near-term revenue generating product, supporting itscore business in cancer and viral vaccine development.
ContactDetails
Proactive Canada
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.